Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001209191-17-041627
Filing Date
2017-06-23
Accepted
2017-06-23 16:01:20
Documents
1
Period of Report
2017-06-21

Document Format Files

Seq Description Document Type Size
1 FORM 4 SUBMISSION doc4.html 4  
1 FORM 4 SUBMISSION doc4.xml 4 3811
  Complete submission text file 0001209191-17-041627.txt   5347
Mailing Address C/O ARBUTUS BIOPHARMA CORP. 100-8900 GLENLYON PARKWAY BURNABY A1 V5J 5J8
Business Address
KARBE FRANK (Reporting) CIK: 0001276700 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-34949 | Film No.: 17927572

Mailing Address 100-8900 GLENLYON PARKWAY BURNABY A1 V5J 5J8
Business Address 100-8900 GLENLYON PARKWAY BURNABY A1 V5J 5J8 604-419-3200
Arbutus Biopharma Corp (Issuer) CIK: 0001447028 (see all company filings)

EIN.: 980597776 | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations